ライフサイエンスコーパス: palpitation

1 e to toxicity (deep venous thrombosis, chest palpitations).

2 ade 1 sinus bradycardia; and one had grade 1 palpitation.

3 le with AF, such as fatigue, dyspnea, and/or palpitations.

4 effects include pallor, tremor, anxiety, and palpitations.

5 mic, or gastrointestinal symptoms, and heart palpitations.

6 mic, or gastrointestinal symptoms, and heart palpitations.

7 s-loop event recording for the evaluation of palpitations.

8 ction presented with shortness of breath and palpitations.

9 ted with progressively worsening dyspnea and palpitations.

10 c for 24 months (Q1-Q3, 16-60); 73% reported palpitations, 47% fatigue, and 30% (near-)syncope.

11 therapy for overall symptoms (-41%, P<0.01), palpitations (-58%, P=0.0001), and dyspnea (-37%, P<0.05

12 overall symptoms (-48% versus -4%, P<0.005), palpitation (-62% versus -5%, P<0.001), dyspnea (-44% ve

13 Except for palpitation after 7 min, the only subjective symptom was

14 milar to adrenaline, to induce sensations of palpitation and dyspnea in healthy individuals (n=23) du

15 lified by the poor correlation found between palpitations and cardiac arrhythmias.

16 History A 47-year-old man presented with palpitations and decreased exercise tolerance.

17 Palpitations and dyspnea are fundamental to the human ex

18 y sensation, with all participants reporting palpitations and dyspnea at the 2 mug dose.

19 B.G. and A.M.) to examine whether triggering palpitations and dyspnea via stimulation of non-chemosen

20 with complaints of intermittent chest pain, palpitations and exertional dyspnoea.

21 re prevalent in women and have symptoms (eg, palpitations and fatigue) that may be confounded with CA

22 ifth decades of life either with symptoms of palpitations and syncope associated with ventricular tac

23 ressors and a family history of intermittent palpitations and syncope in his brother raised suspicion

24 nce; 84 had chest pain with activity; 75 had palpitations and/or tachycardia.

25 in New York Heart Association class 2, 5 had palpitations, and 2 had a history of syncope.

26 Exertional dyspnea, chest pain, palpitations, and ankle swelling were reported by 47 (43

27 ss on standing, which may worsen to syncope, palpitations, and blue-purple ankle discoloration, and i

28 omach pain, fainting, loose stools/diarrhea, palpitations, and sleep problems), even after adjustment

29 extremely anxious with heart rate increases, palpitations, and symptoms of psychological arousal.

30 pical symptoms include dyspnoea, chest pain, palpitations, and syncope.

31 luding anxiety, insomnia, tremulousness, and palpitations, as well as bone loss and possibly increase

32 or establishing a diagnosis in patients with palpitations but are less effective for establishing a d

33 orders are widely used for the evaluation of palpitations, but the optimal duration of monitoring is

34 e effects (such as tachycardia; bradycardia; palpitation; changing PR, QRS, QTc intervals in electroc

35 , they may cause important symptoms, such as palpitations, chest discomfort, breathlessness, anxiety,

36 supplement-related adverse events involving palpitations, chest pain, or tachycardia, and 58.0% (95%

37 sturbance, and tension, and symptoms such as palpitations, dry mouth, and sweating.

38 o recurrent systemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can b

39 significant improvement in several symptoms (palpitations, dyspnea).

40 Type of symptoms (palpitations, fatigue, and [near-]syncope), PVC burden o

41 symptoms including chest pain, dyspnoea, and palpitations, it often mimics more common disorders such

42 Pre-operative symptoms included palpitations (n = 69), edema (n = 30), and previous stro

43 rdiac channelopathy that can be mistaken for palpitations, neurocardiogenic syncope, and epilepsy.

44 nths), new MacroATs, atrial fibrillation, or palpitations occurred in 3 of 16 patients.

45 o record 20 or 30 seconds twice daily and if palpitations occurred.

46 emonstrable cardiac arrhythmias than are the palpitations of other patients.

47 of resting heartbeat, we have found that the palpitations of patients who somatize more and have more

48 Dropouts occurred due to palpitations (one patient on eliglustat), myocardial inf

49 were age at study > or =18 years (OR, 3.3), palpitations (OR, 2.8), prior palliative surgery (OR, 3.

50 repair of the mitral valve, the dyspnea and palpitations resolved.

51 The most common presenting symptoms were palpitations, syncope, and sudden cardiac death (SCD) in

52 d with an increased risk of tachyarrhythmia, palpitations, syncope, and sudden death.

53 ent adverse effect (17 reports), followed by palpitations, tachycardia, or both (13); stroke (10); an

54 ing the vehicle, 22 percent had dizziness or palpitations that did not necessitate stopping the vehic

55 yncopal episode, 11 percent had dizziness or palpitations that necessitated stopping the vehicle, 22

56 In patients referred for evaluation of palpitations, the diagnostic yield of continuous-loop ev

57 everal consequences, ranging from uneventful palpitations to lethal ventricular arrhythmias, in the p

58 verse effects, such as increased heart rate, palpitations, transient decrease in PaO2, and tremor.

59 ess, hot flush, headache, hyperhidrosis, and palpitations were reported most frequently.

60 Innocent murmur and syncope or palpitations with no other indications of cardiovascular